Piramal Pharma has infused a significant ₹ 1,626.49 Cr into PPL Pharma Inc., its wholly-owned step-down subsidiary.

This substantial capital infusion, through preference share subscription by Piramal Healthcare Inc., aims to fortify the subsidiary's financial standing.

The move is a strategic internal deployment of capital to strengthen existing group assets, supporting PPL Pharma Inc.'s ongoing operations and future growth initiatives.

This isn't an external acquisition, but a balance sheet boost for an already owned entity.